Pfizer to Buy Metsera for $7.3 Billion to Enter the Obesity Drug Race
Pfizer executives are confident about the monthly dosing approach of Metsera’s drug, as the drug remains in the patient’s body long enough without worsening side effects between doses. Pfizer announced…